#RKDSummit
LightNews LightNews
edgarvlermamd.medsky.network
Not all #IgAN therapies are created equal
#Nephpearls #RKDSummit #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40928891/
September 26, 2026 at 6:43 PM
edgarvlermamd.medsky.network
Targeting B cells in immune-mediated kidney diseases: conclusions from @kdigo.org Controversies Conference ca. 2026
#Nephpearls #RKDSummit #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/42034308/
September 26, 2026 at 5:13 PM
edgarvlermamd.medsky.network
Microscopic hematuria as a risk factor for #IgAN progression: considering this biomarker in selecting and monitoring patients ca. 2023
#Nephpearls #RKDSummit #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38053974/
September 26, 2026 at 6:20 PM
edgarvlermamd.medsky.network
Adults with #IgAN are at greater risk of adverse kidney outcomes versus nonglomerular CKD and substantially higher risks of heart failure and death compared with no CKD ca. 2026 from @KIReports
#Nephpearls #RKDSummit #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/42027552/
September 26, 2026 at 6:54 PM
edgarvlermamd.medsky.network
Dipstick hemoglobinuria is associated with histologic markers of active disease in #IgAN and may provide clinically relevant information to complement current assessment of disease activity in #IgAN ca. 2026
#Nephpearls #RKDSummit #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/42628835/
September 26, 2026 at 6:28 PM
edgarvlermamd.medsky.network
APRIL is key 🔑 in the development of Antibody-secreting B lymphocytes ca. 2018 from @JASN_News
#IgAN #Nephpearls #RKDSummit #NephSky

👉 pubmed.ncbi.nlm.nih.gov/29326157/
October 11, 2025 at 6:11 PM
edgarvlermamd.medsky.network
Actionable genes in CKD ca. 2024 from @kdigo.org
#RKDSummit #Nephpearls #NephSky

👉 kdigo.org/guidelines/c...
October 11, 2025 at 3:25 PM
edgarvlermamd.medsky.network
Pathogenesis of #IgAN and emerging targets 🎯 ca. 2025
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40796290/
October 11, 2025 at 6:06 PM
edgarvlermamd.medsky.network
Trying to catch up with #IgAN trials⁉️

Check out “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social
#Nephpearls #RKDSummit #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41050133/
October 11, 2025 at 6:22 PM
edgarvlermamd.medsky.network
Spectrum of podocytopathies: Interaction between genetics 🧬 and environment
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/17410103/
October 11, 2025 at 2:19 PM
edgarvlermamd.medsky.network
Which patients should be on SGLT2 inhibitors (SGLT2i) ⁉️

✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#RKDSummit #Nephpearls #NephSky

👉🏼 www.theisn.org/initiatives/...
October 11, 2025 at 2:55 AM
edgarvlermamd.medsky.network
Stages of cardiovascular-kidney-metabolic (CKM) syndrome
#RKDSummit #Nephpearls #Cardiorenal #NephSky

👉 pubmed.ncbi.nlm.nih.gov/37807924/
October 11, 2025 at 12:57 AM
edgarvlermamd.medsky.network
Potential of antinephrin autoantibody measurement for a noninvasive diagnosis of antinephrin-associated podocytopathy ca. 2025 from @kireports.bsky.social
#RKDSummit #Nephpearls

#VisualAbstract by @brianrifkin.bsky.social

👉🏼 pubmed.ncbi.nlm.nih.gov/40814620/
October 11, 2025 at 1:39 PM
edgarvlermamd.medsky.network
Barriers to appropriate medication prescribing and use in CKD ca. 2024
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/39815796/
October 11, 2025 at 1:16 AM
edgarvlermamd.medsky.network
Treatment targets 🎯 in IgA Nephropathy #IgAN and the positioning of drugs ca. 2025 from @kdigo.org
#Nephpearls #RKDSummit #NephSky

📌 Proteinuria >/= 0.5 g/day (or equivalent) ~ at risk of progressive loss of kidney function

👉🏼 kdigo.org/guidelines/i...
October 11, 2025 at 5:41 PM
edgarvlermamd.medsky.network
Genetics 🧬 of FSGS

#VisualAbstract sightings from @kidneyboy.bsky.social @rheaultm.bsky.social @asnpublications.bsky.social

#RKDSummit #Nephpearls

👉🏼 pubmed.ncbi.nlm.nih.gov/30647093/
👉🏼 pubmed.ncbi.nlm.nih.gov/35474271/
👉🏼 pubmed.ncbi.nlm.nih.gov/39190490/
October 11, 2025 at 3:21 PM
edgarvlermamd.medsky.network
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy #IgAN in a Real-World Database ca. 2024 from @asnpublications.bsky.social
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38323871/
October 11, 2025 at 12:47 AM
edgarvlermamd.medsky.network
Why kidney transplants fail ca. 2012
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/22081892/
October 11, 2025 at 8:13 PM
edgarvlermamd.medsky.network
Impact of Using Risk-Based Stratification on Referral of Patients With CKD From Primary Care to Specialist Care in the United Kingdom ca. 2021 from @kireports.bsky.social
#RKDSummit #Nephpearls #NephSky

#VisualAbstract by @hellokidneymd.bsky.social

👉🏼 pubmed.ncbi.nlm.nih.gov/34386668/
October 11, 2025 at 5:54 PM
edgarvlermamd.medsky.network
A stylized representation of the unmet need in a typical adult patient with #IgAN
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/39211339/
October 11, 2025 at 5:36 PM
edgarvlermamd.medsky.network
Theoretical framework for the implementation of GDMT in Type 2 Diabetes (T2D) and CKD ca. 2024
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38620082/
October 11, 2025 at 1:37 AM
edgarvlermamd.medsky.network
Interrelation of mechanistic drivers in early through advanced stages of kidney damage and disease progression in diabetes ca. 2022
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/35661785/
October 11, 2025 at 2:00 AM
edgarvlermamd.medsky.network
DAPA-CKD: SGLT2 inhibitors (SGLT2i) in IgA Nephropathy and FSGS
#RKDSummit #Nephpearls #NephSky

🔬 IgA Nephropathy
pubmed.ncbi.nlm.nih.gov/33878338/
🔬 FSGS
pubmed.ncbi.nlm.nih.gov/34850160/
October 11, 2025 at 3:59 PM
edgarvlermamd.medsky.network
Clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome (NS) ca. 2023
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/36269406/
October 11, 2025 at 1:47 PM
edgarvlermamd.medsky.network
Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy (IgAN) in Adults
#RKDSummit #Nephpearls #NephSky

👉🏼 www.otsuka.co.jp/en/company/n...
October 11, 2025 at 6:16 PM